Page 2896 - Cote clinical veterinary advisor dogs and cats 4th

Boldface page numbers indicate chapter titles. Page numbers followed by a indicate algorithms; b, boxes; e, electronic content; f, figures; and t, tables. 1543

Lysodren. See Mitotane (o,p’DDD) Mammary hyperplasia, 618–620 Mastocytosis
Lysosomal storage diseases, 1283.e1 Manchester terrier splenic, 632
systemic, 634
aseptic necrosis of femoral head in, 80
VetBooks.ir M Mandibular fracture, 362–364, 363f Maternal causes of dystocia, 279
visceral, 632
hydrocephalus in, 481
von Willebrand disease in, 1043
M-proteins. See Bence-Jones urinary proteins
Matulane. See Procarbazine
Ma huang, 240, 463t–464t
periodontal disease and, 777
Macadamia nut toxicosis, 613–614
MacConkey agar, 428 Mandibulectomy, total, 713, 713f, 715 Mauling, 120.e2
Maxillary fractures, 362–364
Macrobid. See Nitrofurantoin Mange. See Acariasis Maxillofacial fracture. See Maxillary fracture
Macrocyclic lactones. See also specific drugs Mannitol McNab, MDR mutation in, 639
for demodicosis, 246 administration and dosage of, 1490 MDMA. See Amphetamine toxicosis
sensitivity to, MDR1 mutation and, 639 for glaucoma, 389 MDR1 mutation, 152, 638–640, 1510.e6–1510.e7,
toxicosis from, 246 for head trauma, 405 1510.e7t
Macrodantin. See Nitrofurantoin for hepatic encephalopathy seizures, 441 Mebendazole, for sparganosis, 928.e3
Macrolide antibiotics, for heartworm disease, 420 for hyperthermia, 422 Mechanical ventilation. See Positive pressure ventilation
Mad itch. See Pseudorabies Mannosidosis, 945.e2–945.e3 (PPV)
Maggot infestation (myiasis), 673–675, 674f Manx cat Mechanosensitive aspiration reflex. See Reverse sneezing
Magnesium, 1364 fecal incontinence in, 537 Meclizine
hypermagnesemia, 1364 neurogenic megacolon in, 202 administration and dosage of, 1490
hypomagnesemia. See Hypomagnesemia sacrocaudal dysgenesis in, 933.e2 toxicosis from, 73
Magnesium ammonium phosphate calculi. See Struvite spina bifida in, 933.e2 for vascular encephalopathy, 294
urolithiasis Maolate, 108 for vestibular disease, 1038
Magnesium ammonium phosphate crystalluria. See Maprotiline toxicosis, 72 Meclofenamic acid, 696
Struvite crystals Marbofloxacin Medetomidine, 1490
Magnesium hydroxide administration and dosage of, 1490 Medial canthal pocket syndrome, 202, 703–704
administration and dosage of, 1490 for Campylobacter enteritis, 143.e4 Medial canthal trichiasis, 273–274
for zinc phosphide intoxication, 1052 for hemotropic mycoplasmosis, 439 Medial glenohumeral ligament disruption, 914
Magnesium sulfate Marie’s disease, 508 Median nerve block, distal, 1130
administration and dosage of, 1490 Marijuana, 625–626 Mediastinal cysts, 640–642
for lead toxicosis, 579 Marin. See Silymarin (silybin) Mediastinal disease, 640–642
Magnetic resonance imaging (MRI) Marking behavior, in cats, 533 and dyspnea, 1219
in lumbosacral stenosis, 593f Maropitant, 160, 376.e4 pneumomediastinum, 640–642
procedure for, 1132–1134, 1133f for acute gastroenteritis, 383 Mediastinal enlargement, 1252.e1
in spinal cord neoplasia, 932–933 for acute hemorrhagic diarrhea, 259–260 Mediastinal hemorrhage, 640–642
in thymoma, 974 for acute vomiting, 25, 259, 1041 Mediastinal lymphoma, 607
Maine coon cat administration and dosage of, 1490 Mediastinal masses, 640–642, 756.e3
chronic heart failure in, 410 for arsenic toxicosis, 79.e2 and cranial vena cava syndrome, 222
hip dysplasia in, 469 for aspirin toxicosis, 83.e3 Mediastinitis, 640–642
hypertrophic cardiomyopathy in, 505 for chemotherapy reactions, 153 spirocercosis and, 934
kidney disease in, 169 for chronic vomiting, 1042 Medicated shampoos, contact time with, for pyoderma,
patellar luxation in, 763 drug interactions, 1510.e1t–1510.e5t 853
Maintenance fluids, 1510.e8 for intestinal pseudo-obstruction, 557.e2 Medications
Major basic protein, 1336 sensitivity to, MDR1 mutation and, 639 adverse reactions to. See Drug adverse reactions
Malamute. See Alaskan malamute for vascular encephalopathy, 294 inhalant administration of. See Inhalant medication
Malassezia dermatitis, 614–616, 615f Maroteaux-Lamy syndrome, 945.e2–945.e3 administration
atopic dermatitis and, 92 Marquis. See Ponazuril Medium-breed dogs. See also specific breeds
Malathion, 718 Mary Jane. See Marijuana coccidioidomycosis in, 184
Maldigestion, chronic diarrhea and, 262 Masitinib, 1490 hormone-responsive incontinence in,
Male dog. See Stud dog Masivet. See Masitinib 1011
Malignant fibrous histiocytoma, 616.e2–616.e3, 927 Mask, for oxygen supplementation, 1146 mitral/tricuspid regurgitation in, 658
injection site and, 550 Massage, prostatic, 1154 panosteitis in, 750
Malignant hemangioendothelioma. See Hemangiosarcoma Masses. See also Neoplasia Medroxyprogesterone acetate, 826
Malignant histiocytosis, 473 abdominal. See Abdominal mass administration and dosage of, 1490
Malignant hyperthermia, 421 cranial vena cava syndrome and, 222 for pituitary dwarfism, 790.e2
Malignant lymphoma, 607. See also Lymphoma cutaneous/subcutaneous, 628–629 for prostatic enlargement, 826
Malignant melanoma. See Melanoma eyelid, 318–319, 319f Medullary rim sign, 584
Malignant nerve sheath tumor, 692 laryngeal, 573–574 Medulloepithelioma, 559
Malignant schwannoma, 927 mediastinal, 640–642 Mefoxin. See Cefoxitin
Malnutrition, 616.e3–616.e5 pancreatic, 629.e2–629.e3 Megacolon, 202–204, 1407a
home-prepared diets and, 616.e5, 697 rectal, 861 Megaesophagus, 508, 642–643
nutritional secondary hyperparathyroidism and, 697 splenic, 629–632, 631f, 1155.e2f botulism and, 127
Malocclusion, 617–618, 618f, 1089 Massive tissue destruction rhabdomyolysis, 1235–1236 congenital, stunted growth and, 946
Maltese Mast cell neoplasm, 1320 diseases associated with, 1252
Chiari-like malformation in, 156 Mast cell tumors, 318, 893–894, 894.e1f hypertrophic osteopathy and, 508
Eisenmenger’s syndrome in, 288.e2 in cats, 632–634 regurgitation and, 873–874
entropion in, 296 description of, 714 thymoma and, 973–975
hydrocephalus in, 481 in dogs, 634–636, 1436a vascular ring anomaly and, 1031.e2
idiopathic tremor syndrome in, 530 hyperemia and, 495 Megaloglobus, 387
patent ductus arteriosus in, 764 oral, 714 Meglumine antimonite
portosystemic shunt in, 814 prognostic panel for, 1364–1365 administration and dosage of, 1490
pyloric outflow obstruction in, 851.e2 round cell tumors and, 893 for leishmaniasis, 580
stomatitis in, 943 staging of, 1068 Meibomian glands
tremors/myoclonus in, 994 Masticatory muscle cyst of, 318
vasculitis in, 1031.e4 atrophy of. See Facial muscle wasting description of, 273–275
von Willebrand disease in, 1043 paralysis of, trigeminal neuritis and, 997.e2 neoplasia of, 318
Malunion, 357 Masticatory myositis, 320, 637–638 tear film abnormalities and, 961.e2
Mambog, 463t–464t Mastiff Melamine and cyanuric acid, in adulterated diets, 37t
Mammary disorders, non-neoplastic, 618–620, 619f acne in, 15 Melamine precursor. See Cyromazine
Mammary gland neoplasia elbow dysplasia in, 288 Melanin deposits, corneal, 205.e2
in cats, 621–623 iris abnormalities in, 563 Melanocytic tumor, 894.e1f. See also Melanoma
in dogs, 623–625 pulmonic stenosis in, 844 Melanocytoma, 559. See also Melanoma
TNM staging of, 621t, 623t tremors/myoclonus in, 994 intraocular, 559
Mammary gland tumors vaginal hyperplasia/prolapse in, 1028 limbic, 207
in cats, 1433a Mastitis, 618–620 Melanoderma, 195
in dogs, 1434a–1435a Mastocytoma. See Mast cell tumor and alopecia, of Yorkshire terrier, 766, 790
www.ExpertConsult.com